Welcome to our dedicated page for AgomAb Therapeutics NV news (Ticker: AGMB), a resource for investors and traders seeking the latest updates and insights on AgomAb Therapeutics NV stock.
Agomab Therapeutics NV reports news centered on its clinical-stage fibro-inflammatory disease pipeline, public-company financing, and intellectual-property position. Company updates have covered ontunisertib in fibrostenosing Crohn's disease, AGMB-447 in idiopathic pulmonary fibrosis, U.S. patent protection for AGMB-447, and regulatory interactions related to clinical-study design.
Recurring AGMB news also includes financial results, cash runway commentary, Nasdaq ADS trading status, initial public offering activity, and annual meeting or governance materials for the Belgian foreign private issuer.
Agomab Therapeutics (Nasdaq: AGMB) announced participation in several 2026 scientific and investor conferences. Events include a poster on AGMB-447 for idiopathic pulmonary fibrosis at the ATS International Conference and multiple fireside chats and investor meetings across New York, London, San Diego, and Boston.
Agomab (NASDAQ: AGMB)/b) reported full-year 2025 results and confirmed 2026 outlook. Key financials: at 31-Dec-2025, and $208M gross IPO proceeds in Feb-2026, expected to fund operations into the first half of 2029.
Clinical: positive STENOVA Phase 2a topline with ontunisertib, FDA/MHRA alignment on Phase 2 designs, USPTO patent for AGMB-447, and planned initiation of two Phase 2 studies in H2 2026; topline OLE and IPF cohort data expected H2 2026.
Agomab (Nasdaq: AGMB) announced the USPTO granted U.S. Patent No. 12,577,230 for AGMB-447, its investigational inhaled, lung-restricted small molecule ALK5 inhibitor. The patent covers composition of matter in the U.S. through at least 2041, excluding potential extensions.
AGMB-447 is in a Phase 1b study for idiopathic pulmonary fibrosis (IPF); healthy-subject data were described as positive and patient-cohort results are expected later in 2026. AGMB-447 is not approved and its safety and efficacy remain unestablished.
Agomab (Nasdaq: AGMB) closed its initial public offering of 12,500,000 ADSs at $16.00 per ADS, generating approximately $200.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The ADSs began trading on the Nasdaq Global Select Market on February 6, 2026.
Joint book-running managers included J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen; the registration statement was declared effective January 30, 2026.
Agomab (Nasdaq: AGMB) priced its initial public offering of 12,500,000 ADSs at $16.00 per ADS, implying gross proceeds of approximately $200.0 million before fees. The ADSs are expected to begin trading on February 6, 2026 and the offering is expected to close on February 9, 2026.
The company granted underwriters a 30‑day option to purchase an additional 1,875,000 ADSs. Joint book‑running managers include J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen.